The Prevalence of Inflammatory Bowel Disease (IBD) in Patients with Multiple Sclerosis (MS): A Systematic Review and Meta-Analysis.

IF 1.7 Q2 MEDICINE, GENERAL & INTERNAL International Journal of Preventive Medicine Pub Date : 2023-06-22 eCollection Date: 2023-01-01 DOI:10.4103/ijpvm.ijpvm_44_22

Amirreza Nasirzadeh, Reza Jahanshahi, Mahsa Ghajarzadeh, Aida Mohammadi, Abdorreza Naser Moghadasi

{"title":"The Prevalence of Inflammatory Bowel Disease (IBD) in Patients with Multiple Sclerosis (MS): A Systematic Review and Meta-Analysis.","authors":"Amirreza Nasirzadeh, Reza Jahanshahi, Mahsa Ghajarzadeh, Aida Mohammadi, Abdorreza Naser Moghadasi","doi":"10.4103/ijpvm.ijpvm_44_22","DOIUrl":null,"url":null,"abstract":"Background: This systematic review and meta-analysis aim to update the pooled prevalence of Inflammatory bowel disease (IBD) in patients with multiple sclerosis (MS).Methods: Two researchers independently and systematically searched PubMed, Scopus, EMBASE, Web of Science, and google scholar. They also searched for references of the included studies, and conference abstracts that were published up to September 2021.Results: The literature search revealed 5719 articles, after deleting duplicates 3616 remained. Finally, 17 studies were included. The pooled prevalence of IBD in MS was 1% (I2 = 96.3%, P < 0.001). The pooled odds ratio of developing IBD in MS cases was 1.36 (95% CI: 1.1-1.6) (I2 = 58.3, P = 0.01).Conclusions: The results of this systematic review and meta-analysis show that the pooled prevalence of IBD in MS patients was 1% and the pooled odds ratio of developing IBD in MS cases was 1.36.","PeriodicalId":14342,"journal":{"name":"International Journal of Preventive Medicine","volume":null,"pages":null},"PeriodicalIF":1.7000,"publicationDate":"2023-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5d/ea/IJPVM-14-81.PMC10580199.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Preventive Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/ijpvm.ijpvm_44_22","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: This systematic review and meta-analysis aim to update the pooled prevalence of Inflammatory bowel disease (IBD) in patients with multiple sclerosis (MS).

Methods: Two researchers independently and systematically searched PubMed, Scopus, EMBASE, Web of Science, and google scholar. They also searched for references of the included studies, and conference abstracts that were published up to September 2021.

Results: The literature search revealed 5719 articles, after deleting duplicates 3616 remained. Finally, 17 studies were included. The pooled prevalence of IBD in MS was 1% (I² = 96.3%, P < 0.001). The pooled odds ratio of developing IBD in MS cases was 1.36 (95% CI: 1.1-1.6) (I² = 58.3, P = 0.01).

Conclusions: The results of this systematic review and meta-analysis show that the pooled prevalence of IBD in MS patients was 1% and the pooled odds ratio of developing IBD in MS cases was 1.36.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

多发性硬化症（MS）患者炎症性肠病（IBD）的患病率：系统综述和荟萃分析。

背景：本系统综述和荟萃分析旨在更新多发性硬化症（MS）患者炎症性肠病（IBD）的合并患病率。方法：两名研究人员独立系统地搜索PubMed、Scopus、EMBASE、Web of Science和谷歌学者。他们还搜索了截至2021年9月发表的纳入研究的参考文献和会议摘要。结果：文献搜索显示了5719篇文章，删除了重复的3616篇。最后，纳入了17项研究。多发性硬化症合并IBD的患病率为1%（I2=96.3%，P<0.001）。多发性痴呆症合并发生IBD的比值比为1.36（95%CI:1.1-1.6）（I2=58.3，P=0.01）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

International Journal of Preventive Medicine MEDICINE, GENERAL & INTERNAL-

CiteScore

3.20

自引率

4.80%

发文量

107

期刊介绍： International Journal of Preventive Medicine, a publication of Isfahan University of Medical Sciences, is a peer-reviewed online journal with Continuous print on demand compilation of issues published. The journal’s full text is available online at http://www.ijpvmjournal.net. The journal allows free access (Open Access) to its contents and permits authors to self-archive final accepted version of the articles on any OAI-compliant institutional / subject-based repository. The journal will cover technical and clinical studies related to health, ethical and social issues in field of Preventive Medicine. Articles with clinical interest and implications will be given preference.